SCHEMBL6681435

SCHEMBL6681435

COc1cccc(COC(=O)C2=Cn3c(c(C)c(=O)n(Cc4ccccc4)c3=O)CO2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.43
MAPT P10636 4/20 0.42
RXFP1 Q9HBX9 2/20 0.42
TP53 P04637 1/20 0.42
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP12 P39900 2/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718675 0.85 MAPT (0.51) THRBMAPTRXFP1TP53ALDH1A1
SCHEMBL6718409 0.84 THRB (0.43) THRBMAPTRXFP1TP53MMP1
SCHEMBL6665653 0.83 MMP1 (0.43) THRBMAPTRXFP1TP53MMP1
SCHEMBL6682079 0.80 NOTUM (0.40) ALDH1A1KDM4ERAB9ATSHRMEN1
SCHEMBL6681574 0.77 ALDH1A1 (0.36) THRBMAPTTP53ALDH1A1KDM4E
SCHEMBL6682041 0.75 MAPK14 (0.39) MAPTALDH1A1KDM4ERAB9ATSHR
SCHEMBL6683643 0.73 MAPT (0.53) MAPTRXFP1TP53ALDH1A1KDM4E
SCHEMBL6678517 0.73 THRB (0.43) THRBMAPTRXFP1TP53MMP1
SCHEMBL6678339 0.72 MAPT (0.51) MAPTRXFP1TP53ALDH1A1KDM4E
SCHEMBL6681686 0.71 MMP1 (0.46) THRBMAPTRXFP1TP53MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 THRB 4700/4885MAPT 1535/4885RXFP1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.